• Publications
  • Influence
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses. Expand
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes and the specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer. Expand
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy. Expand
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value. Expand
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancerExpand
Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.
An increased awareness of the potential risk of ONJ in patients receiving bisphosphonate therapy is needed and close coordination between the treating physician and oral surgeon and/or a dental specialist is strongly recommended in making treatment decisions. Expand
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Patients who develop cardiotoxicity while receiving trastuzumab therapy generally improve on removal of the agent, as demonstrated by the absence of anthracycline-like ultrastructural changes. Expand
Genomic index of sensitivity to endocrine therapy for breast cancer.
The SET index of ER-related transcription predicted survival benefit from adjuvant endocrine therapy, not inherent prognosis, and prior chemotherapy seemed to enhance the efficacy of adjuant endocrine Therapy related to SET index. Expand
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Tumor pathologic features and clinical characteristics examined in 491 women with breast cancer who underwent genetic testing for BRCA mutations suggest that tumors associated with BRCa1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups. Expand
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
The clinical relevancy of the 7-subtype classification of triple-negative breast cancer reported by Lehmann and colleagues is confirmed, and may spur innovative personalized medicine strategies for patients with TNBC. Expand